Cosmetic vs. Drug Claims: Where the FDA Draws the Line

Beauty and wellness brands often launch products as cosmetics while marketing them with therapeutic-sounding benefits. FDA does not classify products based on what founders hope they are — it looks at expressed and implied claims across all materials. One acne "treatment" headline can recharacterize an entire product line.

Classification questions often surface during retailer onboarding, Amazon category review, or influencer campaign planning — well after formulas and packaging are finalized. Early claim audits cost far less than emergency relabeling, reformulation, or pursuing an OTC drug monograph pathway after launch. Natascia Taken, Esq. encourages brands to map intended claims to regulatory categories during product development, not only at the legal review stage before advertising goes live.

How does FDA define cosmetics vs. drugs?

Cosmetics are articles intended to be rubbed, poured, sprinkled, or sprayed on the body for cleansing, beautifying, promoting attractiveness, or altering appearance. Drugs are articles intended to diagnose, cure, mitigate, treat, or prevent disease — or affect the structure or any function of the body. The same product can be both a cosmetic and a drug if it meets both definitions (for example, an antidandruff shampoo). FDA guidance: Is it a cosmetic, a drug, or both? walks through classification examples.

What cosmetic claims are generally permissible?

• Moisturizes dry skin and improves appearance of softness.
• Reduces the appearance of fine lines (appearance claims, not structural change).
• Cleanses pores and removes makeup.
• Adds shine or volume to hair (cosmetic effect).
• Fragrance and color enhancement claims tied to appearance.

What claims push a product toward drug classification?

Claims that a product treats acne, eczema, psoriasis, hair loss, or pigmentation disorders typically indicate drug intended use. Claims about changing skin structure — increasing collagen production, regenerating cells, or healing wounds — also signal drug claims. FDA reviews words, images, before-and-after photos, and consumer testimonials together. FDA cosmetic product claims explains how FDA evaluates claims that may cause a product to be regulated as a drug.

Mechanism-of-action language — "inhibits melanin," "blocks DHT," "kills acne bacteria" — often pushes products toward drug status even when the headline uses softer cosmetic framing. Ingredient names associated with drug outcomes (hydrocortisone, minoxidil, benzoyl peroxide at drug levels) can reinforce intended use analysis. Brands should review ingredient callouts and clinical study summaries on product pages with the same scrutiny as primary headlines.

Does FDA look at website and social media claims?

Yes. FDA evaluates intended use from the totality of labeling and promotional materials, including websites, Amazon listings, influencer posts, and email campaigns. A compliant cosmetic label paired with a disease-treatment claim on the homepage still supports drug classification. Cross-channel consistency is essential.

Appearance vs. treatment wording

"Reduces the appearance of wrinkles" is generally cosmetic framing. "Eliminates wrinkles" or "reverses aging" suggests structural change or treatment. "Helps with breakouts" may be ambiguous; "treats acne" is drug language. Natascia Taken, Esq. often reviews claim libraries with clients to replace treatment verbs with appearance-based alternatives where appropriate.

How does cosmetic vs. drug classification affect labeling?

Cosmetic labeling has specific requirements for INCI ingredient lists, principal display panels, and responsible person contact information. Drug products — including OTC drugs — follow different labeling conventions, including Drug Facts panels and NDC numbers where applicable. See our cosmetic labeling requirements checklist for baseline cosmetic label elements. Mislabeling a drug product as a conventional cosmetic creates separate FDA exposure beyond claim wording alone.

What happens if FDA views a cosmetic as an unapproved drug?

Products marketed as drugs without FDA approval may be subject to warning letters, import alerts, seizure, or injunction. Retailers may delist products. Corrective action typically requires revising claims across all channels, updating labels, and sometimes reformulating or pursuing formal drug clearance if the company intends to keep therapeutic claims.

MoCRA added registration, listing, and adverse event reporting obligations for cosmetics, but it did not change the fundamental cosmetic-versus-drug classification framework. A brand can be MoCRA-compliant on facility registration while still marketing an unapproved drug if claims cross the line. See our MoCRA compliance checklist for operational requirements that run parallel to — but do not replace — claim classification review.

How should brands assess cosmetic vs. drug claim risk?

Conduct a claim audit across label, website, ads, retailer copy, and influencer scripts. Flag disease names, treatment verbs, and mechanism-of-action language. Compare against FDA warning letter trends in your category. This educational overview does not determine how FDA would classify any specific product.

Warning letter trends in skincare, haircare, and sunless tanning categories show FDA consistently reviewing Amazon listings, social posts, and FAQ pages alongside primary labels. Archive historical marketing versions so your team can demonstrate corrective action if classification questions arise. When in doubt, narrow claims to appearance-based language and consult counsel before pursuing treatment positioning.

Dual-use ingredients — salicylic acid, benzoyl peroxide, zinc pyrithione — appear in both cosmetic and OTC drug products at different concentrations with different allowed claims. Marketing copy should align with the regulatory pathway chosen for that SKU, not with generic ingredient benefits from supplier marketing sheets. A cosmetic serum cannot borrow OTC acne treatment claims simply because it contains an ingredient also used in drug products.